Ergoteles’s AbbVie ABBV Stock Holding History

Ergoteles’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,753	Closed	-$2.79M	–	1399
2022 Q3	$2.79M	Buy	20,753 +18,178	+706%	+$2.61M	0.1%	206
2022 Q2	$394K	Sell	2,575 -3,030	-54%	-$463K	0.01%	962
2022 Q1	$909K	Buy	5,605 +847	+18%	+$123K	0.03%	465
2021 Q4	$644K	Buy	+4,758	New	+$562K	0.03%	548
2021 Q1	–	Sell	-54,187	Closed	-$5.81M	–	761
2020 Q4	$5.81M	Buy	+54,187	New	+$5.21M	0.19%	119

Other funds holding ABBV

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ergoteles's ABBV Position: Q4 2022 in Review

Ergoteles sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 20,753 shares — an estimated $2.79M sold.

Ergoteles first reported a position in ABBV in Q4 2020 and held it in 5 quarters. The position peaked at $5.81M in Q4 2020. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

Ergoteles reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 20,753 AbbVie shares in Q4 2022, an estimated $2.79M.
Ergoteles first reported a position in AbbVie in Q4 2020 and held it in 5 quarters.
Ergoteles's AbbVie position peaked at $5.81M in Q4 2020.
3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.